Fibromyalgia Trial, Recruiting NCT07293767 Sponsor: Ain Shams University Condition: Fibromyalgia
Back to Fibromyalgia

Fibromyalgia Trial, Recruiting

NCT07293767
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give written consent to participate.
  • People whose fibromyalgia meets specific scoring criteria set by the American College of Rheumatology (2016 guidelines), based on how widespread their pain is and how severe their symptoms are (confirm with trial site for exact score details).
  • People who are over 18 years old (both men and women).
  • People who have had their fibromyalgia formally diagnosed by a rheumatology specialist.
  • People who continue to experience persistent pain despite already being on standard treatment.
  • People who have not been taking the medications Daflon or Legalon for at least the past 6 months.

Who may not be able to join:

  • People whose pain is caused by another condition — such as nerve pain from diabetes or shingles — that could make it difficult to measure fibromyalgia pain accurately.
  • People with widespread joint or muscle pain caused by other conditions such as rheumatoid arthritis or lupus.
  • People who have a known allergy to silymarin, diosmin, or hesperidin.
  • People with cognitive difficulties that may affect their ability to understand the study, complete questionnaires, or follow the treatment plan.
  • People who are pregnant, planning to become pregnant, or currently breastfeeding.
  • People with significant other health conditions, including kidney problems, severe liver disease, chronic hepatitis C, or a history of alcohol or drug addiction.
  • People with severe or currently uncontrolled major depression or anxiety disorders.
  • People who are unlikely to be able to follow the medication schedule as required by the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 01064897439

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
16 November 2024
Est. completion
15 January 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

pain assessment through Fibromyalgia impact questionnaire (FIQ)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov